{"analyses":[{"ciLowerLimit":"0.99","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.70","estimateComment":"Reference level = RT + cisplatin","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.97","paramType":"Hazard Ratio (HR)","paramValue":"1.3","statisticalComment":"One-sided significance level of 0.025","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.2","upperLimit":"23.7","value":"19.9"},{"groupId":"OG001","lowerLimit":"21.7","upperLimit":"30.1","value":"25.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"444"}],"units":"Participants"}],"description":"Local-regional failure is defined as time from randomization to date of failure (local or regional progression), or distant disease progression, or death from any cause. Patients last known to be alive without progression are censored at the date of last contact. Distant disease progression is considered a competing risk. Local or regional progression is defined as an estimated increase in the size of the tumor (product of the perpendicular diameters of the two largest dimensions) of greater than 25%, taking as reference the smallest value of all previous measurements or appearance of new areas of malignant disease. Distant progression is defined as clear evidence of distant metastases. Three-year rates were estimated by the cumulative incidence method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin","id":"OG000","title":"RT + Cisplatin"},{"description":"Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin plus cetuximab","id":"OG001","title":"RT + Cisplatin + Cetuximab"}],"paramType":"NUMBER","populationDescription":"Randomized eligible patients with follow-up data","reportingStatus":"POSTED","timeFrame":"From randomization until 434 failures have occurred, approximately 5 years from start of study. (Patients are followed until death or study termination, whichever occurs first.)","title":"Local-regional Failure (LRF) (3-year Rate Reported)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}